![Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors](https://www.spandidos-publications.com/article_images/ol/17/1/ol-17-01-0616-g00.jpg)
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
![Medicina | Free Full-Text | Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice Medicina | Free Full-Text | Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice](https://www.mdpi.com/medicina/medicina-60-00168/article_deploy/html/images/medicina-60-00168-g001.png)
Medicina | Free Full-Text | Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
![Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer](https://probiologists.com/Uploads/WebImages/7-638125463035357887-cancer-biology-protein-4-1-002-g001.jpg)
Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer
![Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC](https://europepmc.org/articles/PMC4863770/bin/medi-95-e3518-g001.jpg)
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC
![Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fmodpathol.2013.153/MediaObjects/41379_2014_Article_BFmodpathol2013153_Fig1_HTML.jpg)
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
![Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors](https://www.spandidos-publications.com/article_images/ol/17/1/ol-17-01-0616-g02.jpg)
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
![Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens | Virchows Archiv Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens | Virchows Archiv](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00428-020-02818-4/MediaObjects/428_2020_2818_Fig2_HTML.png)
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens | Virchows Archiv
![Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes | springermedizin.de Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes | springermedizin.de](https://media.springernature.com/lw150/springer-static/cover/journal/10549/178/2.jpg?as=jpg)
Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes | springermedizin.de
![การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology](https://www.asianarchpath.com/storage/AAP_Technical_V2N1_2020/AAP_Technical_V2N1_2020.png)
การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology
Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study | PLOS ONE
![MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13000-022-01209-4/MediaObjects/13000_2022_1209_Fig1_HTML.png)
MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text
![Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fmodpathol.2013.153/MediaObjects/41379_2014_Article_BFmodpathol2013153_Fig2_HTML.jpg)
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
![Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer | Scientific Reports Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-022-11411-5/MediaObjects/41598_2022_11411_Fig2_HTML.png)
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer | Scientific Reports
![Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1756-0500-5-376/MediaObjects/13104_2011_Article_1552_Fig1_HTML.jpg)
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text
![PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a33aa443a365c6282bd5449f8899f125cb99c7a9/3-Table3-1.png)
PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar
![Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2020/11/Figure-1-Concordance-between-immunohistochemistry-and-PAM50-using-two-different-cut-off-values.jpg)
Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal
![PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/60a5e17db2ebec70ad7ebb9addd7b2a5f3bf9992/6-Figure1-1.png)